“We are excited to work with Pierre Fabre, a leader in precision oncology, on an international collaboration to explore ERAS-007 in combination with encorafenib and cetuximab in BRAF mCRC,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “This partnership complements our existing CTCSA with Pfizer for encorafenib within the United States and other markets. Resistance mechanisms, particularly through MAPK reactivation, limit long-term benefit with current standard of care BRAF-targeted treatments. By blocking RAS/MAPK pathway signaling at the most distal node, ERK1/2, ERAS-007 can potentially prevent pathway reactivation.”
